ASCL1 and small cell lung carcinoma: Additionally, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is highly expressed in ASCL1-driven SCLC and represents a promising therapeutic target, with labetuzumab govitecan being a potential targeting agent [18].